Updated results from the phase III MARIPOSA-2 study showed Rybrevant (amivantamab-vmjw) combined with chemotherapy led to consistent benefit across post-progression outcomes in adult patients with previously treated NSCLC with epidermal growth factor receptor exon 19 deletions or L858R substitution mutations.
Ten-year follow-up data from CheckMate-067, a randomized, double-blind, phase III clinical trial showed continued durable improvement in survival with first-line Opdivo (nivolumab) plus Yervoy (ipilimumab) therapy and Opdivo monotherapy, versus Yervoy alone, in patients with previously untreated advanced or metastatic melanoma.
Data from the phase I/II study of Rina-S (rinatabart sesutecan), an investigational folate receptor-alpha-targeted, Topo1 antibody-drug conjugate, demonstrated a confirmed objective response rate of 50.0% (95% CI) in ovarian cancer patients treated with Rina-S 120 mg/m2 once every three weeks, regardless of FRα expression levels.
The NRG Oncology NSABP B-39/RTOG 0413 clinical trial compared whole-breast irradiation to accelerated partial-breast irradiation and determined that APBI was not statistically equivalent to WBI in local tumor control. The secondary outcome for the trial was quality-of-life.
Investigators at UC Davis Comprehensive Cancer Center and UCLA Health’s Jonsson Comprehensive Cancer Center report they have manipulated mesenchymal stem cells to create four different sarcoma models.
Treatment with a combination of haloperidol and lorazepam reduced symptoms of agitated delirium, a common end-of-life condition for patients with advanced cancers, compared with haloperidol alone, according to a study led by researchers at The University of Texas MD Anderson Cancer Center.
Incyte announced early clinical data for INCB123667, a highly selective CDK2 inhibitor, in patients with advanced solid tumors.
West African genetic ancestry was associated with increased prostate cancer among men living in disadvantaged neighborhoods but not among men living in more affluent neighborhoods, according to a new study led by NIH researchers. The findings suggest that neighborhood environment may play a role in determining how genetic ancestry influences prostate cancer risk.
The Wistar Institute’s president and CEO, Dario C. Altieri, and his team have demonstrated the role of Parkin—a protein implicated in Parkinson’s disease—in the body’s innate immune response to cancer. Parkin is not expressed in several cancers. Altieri and his team engineered cancer cells to re-express Parkin and found that Parkin contributes to the production of interferons, which activate and attract T cells to fight the tumor. The lab’s findings were published in The Journal of Clinical Investigation.
Friends of Cancer Research announced the publication of a commentary on the significance of pragmatic clinical trials in ESMO Real World Data and Digital Oncology.